SMART PILL MARKET SET TO GROW TO OVER $2.4BN IN 2017

07 August 2017
Pharma

Visiongain has launched a new pharma report Smart Pill Market World Market Forecast 2017-2027: See Prospects for Capsule Endoscopy, Drug Delivery and Patient Monitoring in North America, South America, Europe, Asia-Pacific and the Rest of the World

Smart Pill technology is a revolutionary technological innovation that has bridged the gap between healthcare and digital technology. Smart Pills are basically medical devices and small embedded electronic appliances such as sensors, cameras and trackers. This electronic device can be easily swallowed and it also provides complete evaluation of the gastrointestinal tract (GIT).

The emergence of these ‘healthcare-cum-technology’ devices has addressed the soaring need for better diagnostics and monitoring. It has outperformed the conventional GI monitoring endoscopy with more convenient Smart Pill technology, which has now become the standard non-invasive diagnosis technique for motility disorders. Moreover, it helps physicians in real-time patient monitoring through remote controlling options.

The lead Visiongain report analyst for this report commented; “The Value Chain of the Smart Pill technology market includes different stakeholders such as Raw material suppliers, Manufacturers, Suppliers/distributers, Service providers, and Payers (Hospitals and clinics). Each stakeholder plays a different role and the activities indicate the direct influence that production processes have on the Smart Pill technology market. The functioning of primary activities is supplemented by supporting activities without any disruption in the production process. These support activities in the Smart Pill technology include technological advancements, patent protection, research and development activities along with government regulations and reimbursement. Primary and secondary activities are greatly influenced by external stakeholders such as suppliers, end-users and payers (Hospitals and clinics).

However, clinicians, doctors and gastroenterologist sometimes prefer traditional endoscopy procedures due to its comparatively lower cost than capsule endoscopy systems. Moreover, in under developed regions like Africa, doctors for the sake of patient’s affordability mostly prefer traditional endoscopy techniques. However, the diagnostic results offered by the capsule endoscopy technique is far better than traditional endoscopy techniques, thus, the smart pill market is expected to increase significantly in size over the forecast period”

The Smart Pill Market World Market Forecast market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global smart pill market Cerner Corporation,
GE Healthcare, Proteus Digital Health Inc, Boston Scientific Corporation, Capso Vision Inc., Fujifilm Holdings Corporation, Medtronic PLC, Bio-Image Drug Delivery Limited (BDD), Hoya Corporation (PENTAX Medical) and Olympus Corporation.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever